Identification and validation of a new prognostic signature based on cancer-associated fibroblast-driven genes in breast cancer

Table 1 Clinical and pathological characteristics of patients with breast cancer in The Cancer Genome Atlas cohort

Variables	n	%
Age, yr
< 60	570	53.17
≥ 60	571	46.74
NA	1	0.09
Pathologic-T
T1	274	25.56
T2	621	57.93
T3	133	12.41
T4	40	3.73
TX	4	0.37
Pathologic-N
N0	502	46.83
N1	355	33.12
N2	118	11.01
N3	76	7.08
NA	21	1.96
Pathologic-M
M0	896	83.58
M1	22	2.05
NA	154	14.37
Stage
Stage I	176	16.41
Stage II	608	56.72
Stage III	246	22.95
Stage IV	20	1.87
NA	22	2.05
PAM50
Basal	136	12.69
Luminal-A	413	38.53
Luminal-B	185	17.25
Her2	66	6.16
Normal	22	2.05
NA	250	23.32

Table 2 Relationship between expression level of FKBP14 and clinical features in breast cancer

Variables	n	Low expression of FKBP14 (n = 40)	High expression of FKBP14 (n = 40)	χ2	P value
Age (yr)				0.056	0.813
≤ 60	53	27 (67.5)	26 (65)
> 60	27	13 (32.5)	14 (35)
Tumor size				10.769	0.002
≤ 2 cm	28	21 (52.5)	7 (17.5)
> 2 cm	52	19 (47.5)	33 (82.5)
Lymph node metastasis				25.208	< 0.001
No	48	35 (87.5)	13 (32.5)
Yes	32	5 (12.5)	27 (67.5)
Stage				11.250	0.001
I-II	64	38 (95)	26 (65)
III	16	2 (5)	14 (35)
Subtype				3.660	0.056
Triple negative	17	12 (30)	5 (12.5)
Non-triple negative	63	28 (70)	35 (87.5)